The Efficacy of an N-Acetylcysteine–Antibiotic Combination Therapy on IAchromobacter xylosoxidans/I in a Cystic Fibrosis Sputum/Lung Cell Model

• Published in: Biomedicines Vol. 10; no. 11
• Main Authors: Aiyer, Aditi, Das, Theerthankar, Whiteley, Gregory S, Glasbey, Trevor, Kriel, Frederik H, Farrell, Jessica, Manos, Jim
• Format: Journal Article
• Language: English
• Published: MDPI AG 01.11.2022
• Subjects: Drug therapy, Combination; Methods; Australia
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10112886

Cystic fibrosis (CF) is a disorder causing dysfunctional ion transport resulting in the accumulation of viscous mucus. This environment fosters a chronic bacterial biofilm-associated infection in the airways. Achromobacter xylosoxidans, a gram-negative aerobic bacillus, has been increasingly associated with antibiotic resistance and chronic colonisation in CF. In this study, we aimed to create a reproducible model of CF infection using an artificial sputum medium (ASMDM-1) with bronchial (BEAS-2B) and macrophage (THP-1) cells to test A. xylosoxidans infection and treatment toxicity. This study was conducted in three distinct stages. First, the tolerance of BEAS-2B cell lines and two A. xylosoxidans strains against ASMDM-1 was optimised. Secondly, the cytotoxicity of combined therapy (CT) comprising N-acetylcysteine (NAC) and the antibiotics colistin or ciprofloxacin was tested on cells alone in the sputum model in both BEAS-2B and THP-1 cells. Third, the efficacy of CT was assessed in the context of a bacterial infection within the live cell/sputum model. We found that a model using 20% ASMDM-1 in both cell populations tolerated a colistin–NAC-based CT and could significantly reduce bacterial loads in vitro (~2 log[sub.10] CFU/mL compared to untreated controls). This pilot study provides the foundation to study other bacterial opportunists that infect the CF lung to observe infection and CT kinetics. This model also acts as a springboard for more complex co-culture models.